NBD-14270

• Description :

  NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC50>100 μM) [1][2].

• UNSPSC :

  12352005

• Target :

  HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/nbd-14270.html

• Concentration :

  10mM

• Purity :

  99.53

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  FC(F)(C1=CC=C(N=C1)C2=CC(C)=C(N2)C(N[C@H](C3=NC=C(S3)CO)CN)=O)F

• Molecular Formula :

  C18H18F3N5O2S

• Molecular Weight :

  425.43

• References & Citations :

  [1]Francesca Curreli, et al. Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. J Med Chem. 2020 Feb 27;63 (4) :1724-1749.|[2]Natalie Losada, et al. HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites. J Med Chem. 2021 Nov 25;64 (22) :16530-16540.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HIV-1

• CAS Number :

  [2411819-82-2]